Provided are a condensed cyclic compound and an organic light-emitting device. The condensed cyclic compound is represented by Formula 1: ##STR00001## Details about the constituents of Formula 1 is disclosed.

Universally usable process for reducing the chlorine content of organotetraphosphites.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6, M.sup.1, M.sup.2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

##STR00001##

A condensed cyclic compound which improves emission life and efficiency and an organic electroluminescence device is provided. The condensed cyclic compound according to the inventive concept is represented by the following

##STR00001##

where each of X, Y and Z is independently a substituted or unsubstituted pentagonal hydrocarbon ring, a substituted or unsubstituted hexagonal hydrocarbon ring, a substituted or unsubstituted pentagonal heterocycle, or a substituted or unsubstituted hexagonal heterocycle, the pentagonal heterocycle and the hexagonal heterocycle each independently includes one heteroatom, each of a and b is independently 0 or 1, and Ar.sub.1 is a substituted or unsubstituted aryl group having 6 to 30 carbon atoms for forming a ring.

Catalyst compositions containing phosphine-imino-quinoline ligands and transition metal complexes having phosphine-imino-quinoline ligands are disclosed. These catalyst compositions can be used in ethylene oligomerization processes to produce 1-hexene and 1-octene.

The invention relates to prodrug compounds of formula I:

##STR00001##

wherein R.sup.2, R.sup.3, R.sup.5, R.sup.7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.

The invention relates to prodrug compounds of formula I:

##STR00001##

wherein R.sup.2, R.sup.3, R.sup.5, R.sup.7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.

A condensed cyclic compound and an organic light-emitting device including the condensed cyclic compound, the condensed cyclic compound being represented by one of Formulae 1-1 to 1-8 described herein.

Provided are a condensed cyclic compound and an organic light-emitting device. The condensed cyclic compound is represented by Formula 1:

##STR00001##

Details about the constituents of Formula 1 is disclosed.

Universally usable process for reducing the chlorine content of organotetraphosphites.